Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG protocol 90-20)
- 1 October 1996
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 36 (3) , 673-680
- https://doi.org/10.1016/s0360-3016(96)00336-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Cancer statistics, 1993CA: A Cancer Journal for Clinicians, 1993
- The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: Results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Epidemiologic evidence regarding predisposing factors to prostate cancerThe Prostate, 1990
- Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug scheduleInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508International Journal of Radiation Oncology*Biology*Physics, 1984
- Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: A preliminary reportInternational Journal of Radiation Oncology*Biology*Physics, 1984
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981
- Is tumour radiosensitization by misonidazole a general phenomenon?British Journal of Cancer, 1980
- Hypoxic Sensitizers — Implications for Radiation TherapyNew England Journal of Medicine, 1979